Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Alexion to pay more than $21M to resolve SEC FCPA charges » 08:45
07/02/20
07/02
08:45
07/02/20
08:45
ALXN

Alexion

$112.31 /

+0.03 (+0.03%)

The Securities and…

The Securities and Exchange Commission announced that Boston-based pharmaceutical company Alexion Pharmaceuticals has agreed to pay more than $21M to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act. According to the SEC's order, two Alexion subsidiaries made payments to foreign government officials to secure favorable treatment for Alexion's primary drug, Soliris. The order finds that, from 2010 to 2015, Alexion Turkey paid Turkish government officials to improperly influence them to approve patient prescriptions and provide other favorable regulatory treatment for Soliris. The order similarly finds that from 2011 to 2015, Alexion Russia made improper payments to Russian government health care officials to favorably influence the regulatory treatment of and the budget allocated to Soliris as well as to increase the number of approved Soliris prescriptions. Alexion's internal accounting controls failed to detect and prevent payments to foreign government officials by its subsidiaries," said Melissa Hodgman, an Associate Director in the SEC's Division of Enforcement. "Companies in frequent contact with foreign officials need to ensure that their internal controls appropriately address such risks." Without admitting or denying the SEC's findings, Alexion agreed to cease and desist from committing violations of the books and records and internal accounting controls provisions of the FCPA and pay $14.2M in disgorgement, $3.78M in prejudgment interest, and a $3.5M penalty.

ShowHide Related Items >><<
ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

ALXN Alexion
$112.31 /

+0.03 (+0.03%)

Monday
Hot Stocks
Alexion announces EMA approval of ULTOMIRIS » 05:45
06/29/20
06/29
05:45
06/29/20
05:45
ALXN

Alexion

$113.60 /

+0.08 (+0.07%)

Alexion Pharmaceuticals…

Alexion Pharmaceuticals announced that the European Commission has approved ULTOMIRIS-the first and only long-acting C5 complement inhibitor administered every eight weeks-for the treatment of adults and children with a body weight of 10 kg or above with atypical hemolytic uremic syndrome, or aHUS, who are complement inhibitor treatment-naive or have received SOLIRIS for at least three months and have evidence of response to eculizumab. Alexion said in a release, "The European Commission approval is based on data from two global, single-arm open-label studies of ULTOMIRIS - one in adults and one in children, referred to as pediatrics in the study - with aHUS. Both studies are ongoing. A total of 18 out of 21 complement inhibitor treatment-naive children and 56 out of 58 complement inhibitor treatment-naive adults were enrolled and included in the interim analysis. The FDA approved ULTOMIRIS for the treatment of aHUS to inhibit TMA for adult and pediatric (one month of age and older) patients in October 2019."

ShowHide Related Items >><<
ALXN Alexion
$113.60 /

+0.08 (+0.07%)

ALXN Alexion
$113.60 /

+0.08 (+0.07%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
ALXN Alexion
$113.60 /

+0.08 (+0.07%)

ALXN Alexion
$113.60 /

+0.08 (+0.07%)

ALXN Alexion
$113.60 /

+0.08 (+0.07%)

ALXN Alexion
$113.60 /

+0.08 (+0.07%)

Over a week ago
Options
Alexion put volume heavy and directionally bearish » 14:35
06/24/20
06/24
14:35
06/24/20
14:35
ALXN

Alexion

$112.63 /

-2.81 (-2.43%)

Bearish flow noted in…

Bearish flow noted in Alexion with 1,265 puts trading, or 1.2x expected. Most active are 7/24 weekly 100 puts and Sep-20 100 puts, with total volume in those strikes near 1,000 contracts. The Put/Call Ratio is 3.45, while ATM IV is up nearly 4 points on the day. Earnings are expected on July 29th.

ShowHide Related Items >><<
ALXN Alexion
$112.63 /

-2.81 (-2.43%)

ALXN Alexion
$112.63 /

-2.81 (-2.43%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
ALXN Alexion
$112.63 /

-2.81 (-2.43%)

ALXN Alexion
$112.63 /

-2.81 (-2.43%)

ALXN Alexion
$112.63 /

-2.81 (-2.43%)

ALXN Alexion
$112.63 /

-2.81 (-2.43%)

Hot Stocks
Alexion announces Phase 3 Ultomiris study met primary endpoint » 09:24
06/24/20
06/24
09:24
06/24/20
09:24
ALXN

Alexion

$115.44 /

-1.47 (-1.26%)

Alexion announced topline…

Alexion announced topline results from a Phase 3 study of weekly self-administered subcutaneous, or SC, Ultomiris in adults with paroxysmal nocturnal hemoglobinuria, or PNH. The ongoing study met its primary objective of pharmacokinetic, or PK-based non-inferiority of Ultomiris subcutaneous versus intravenous, or IV, Ultomiris at Day 71. Pending completion of the study, including collection of 12-month safety data as agreed to with the FDA, Alexion now expects to file for approval in the U.S. and E.U. for the Ultomiris subcutaneous formulation and device combination in PNH and atypical hemolytic uremic syndrome in Q3 of 2021. This ongoing global Phase 3, randomized, open-label, parallel-group, multicenter study is evaluating Ultomiris SC compared with Ultomiris IV. The study enrolled 136 adults with PNH who are clinically stable and have previously been treated with Soliris for at least three months prior to study entry. The study's primary objective is to evaluate PK noninferiority of Ultomiris SC compared with Ultomiris IV, as assessed by Ultomiris serum trough concentration at Day 71. The study remains ongoing to assess secondary endpoints, including safety, immunogenicity and various PK/PD, quality of life, device performance and efficacy measures. Patients were stratified by weight groups and then randomized 2:1 to receive either Ultomiris SC or Ultomiris IV. All patients received an initial IV loading dose on Day 1. On Day 15, patients in the ULTOMIRIS SC group began receiving a once-weekly self-administered fixed-dose of Ultomiris SC, and patients in the Ultomiris IV group received a single infusion of the approved weight-based IV dose. The study met its primary objective, with Ultomiris SC demonstrating PK-based non-inferiority versus Ultomiris IV at Day 71. Serum free C5 concentrations were maintained below the target threshold in all patients, and mean lactate dehydrogenase levels remained stable below the upper limit of normal. Preliminary safety data through the 71-day randomized treatment period of the study were consistent with the known safety profile of Ultomiris and did not result in any unexpected safety findings. No adverse events led to withdrawal of study drug in either arm. No serious adverse device effects or meningococcal cases were reported, and no anti-drug antibodies were observed. Of the 135 patients who completed the randomized controlled treatment portion of the study, all but one participant chose to continue in the ongoing SC-only extension period, where all patients are receiving weekly Ultomiris SC for up to an additional 182 weeks. The extension period will provide 12 months of safety data required for regulatory submissions to applicable health authorities, now anticipated Q3 of 2021 to accommodate all regulatory requirements for this combination device filing.

ShowHide Related Items >><<
ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
ALXN

Alexion

$115.44 /

-1.47 (-1.26%)

, JNJ

Johnson & Johnson

$142.86 /

-0.52 (-0.36%)

, NBIX

Neurocrine

$127.61 /

+0.17 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.86 /

-3 (-1.75%)

, ALNY

Alnylam

$152.00 /

-0.91 (-0.60%)

, BTAI

BioXcel Therapeutics

$58.53 /

+1.57 (+2.76%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
SRPT Sarepta
$168.86 /

-3 (-1.75%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
ALXN

Alexion

$116.91 /

-2.36 (-1.98%)

, JNJ

Johnson & Johnson

$143.38 /

-0.63 (-0.44%)

, NBIX

Neurocrine

$127.44 /

-0.65 (-0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$171.86 /

+3.36 (+1.99%)

, ALNY

Alnylam

$152.91 /

+3.23 (+2.16%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

Conference/Events
BofA to hold a virtual conference » 08:54
06/22/20
06/22
08:54
06/22/20
08:54
ALXN

Alexion

$119.27 /

+3 (+2.58%)

, JNJ

Johnson & Johnson

$144.01 /

+0.46 (+0.32%)

, NBIX

Neurocrine

$128.09 /

+7.06 (+5.83%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.50 /

+3.27 (+1.98%)

, ALNY

Alnylam

$149.68 /

+7.67 (+5.40%)

, BTAI

BioXcel Therapeutics

$52.69 /

-2.16 (-3.94%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
06/08/20 Piper Sandler
Sarepta limb-girdle muscular dystrophy data 'look great,' says Piper Sandler
ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

Conference/Events
Piper Sandler biotechnology analysts to hold an analyst/industry conference call » 12:25
06/16/20
06/16
12:25
06/16/20
12:25
MNTX

Manitex

$4.40 /

+0.2 (+4.76%)

, ARGX

Argenx

$222.95 /

+2.68 (+1.22%)

, ALXN

Alexion

$111.31 /

+1.11 (+1.01%)

, IMVT

Immunovant

$26.89 /

+1.14 (+4.43%)

Biotechnology Analysts…

Biotechnology Analysts Van Buren & Tenthoff, along with a neurologist at the Duke Neurological Disorders Clinic, discuss the recent Momenta and Argenx data updates on an Analyst/Industry conference call to be held on June 16 at 1 pm.

ShowHide Related Items >><<
MNTX Manitex
$4.40 /

+0.2 (+4.76%)

IMVT Immunovant
$26.89 /

+1.14 (+4.43%)

ARGX Argenx
$222.95 /

+2.68 (+1.22%)

ALXN Alexion
$111.31 /

+1.11 (+1.01%)

MNTX Manitex
$4.40 /

+0.2 (+4.76%)

11/08/19
Fly Intel: Top five analyst initiations
11/08/19 Roth Capital
Manitex resumed with a Buy at Roth Capital
ARGX Argenx
$222.95 /

+2.68 (+1.22%)

06/16/20 SVB Leerink
Momenta's nipocalimab data positive for Immunovant '1401, says SVB Leerink
06/15/20 Stifel
Stifel reiterates Buy on Momenta following 'positive' nipocalimab results in MG
06/15/20 Piper Sandler
Piper Sandler reiterates Overweight on Momenta after 'solid' Nipocalimab data
05/29/20 JPMorgan
Argenx price target raised to $246 from $179 at JPMorgan
ALXN Alexion
$111.31 /

+1.11 (+1.01%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
IMVT Immunovant
$26.89 /

+1.14 (+4.43%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
ALXN Alexion
$111.31 /

+1.11 (+1.01%)

ALXN Alexion
$111.31 /

+1.11 (+1.01%)

ARGX Argenx
$222.95 /

+2.68 (+1.22%)

ALXN Alexion
$111.31 /

+1.11 (+1.01%)

ALXN Alexion
$111.31 /

+1.11 (+1.01%)

Conference/Events
Piper Sandler biotechnology analysts to hold an analyst/industry conference call » 09:39
06/16/20
06/16
09:39
06/16/20
09:39
MNTX

Manitex

$4.20 /

+ (+0.00%)

, ARGX

Argenx

$220.27 /

+5.82 (+2.71%)

, ALXN

Alexion

$110.20 /

+0.97 (+0.89%)

, IMVT

Immunovant

$25.75 /

+1.8 (+7.52%)

Biotechnology Analysts…

Biotechnology Analysts Van Buren & Tenthoff, along with a neurologist at the Duke Neurological Disorders Clinic, discuss the recent Momenta and Argenx data updates on an Analyst/Industry conference call to be held on June 16 at 1 pm.

ShowHide Related Items >><<
MNTX Manitex
$4.20 /

+ (+0.00%)

IMVT Immunovant
$25.75 /

+1.8 (+7.52%)

ARGX Argenx
$220.27 /

+5.82 (+2.71%)

ALXN Alexion
$110.20 /

+0.97 (+0.89%)

MNTX Manitex
$4.20 /

+ (+0.00%)

11/08/19
Fly Intel: Top five analyst initiations
11/08/19 Roth Capital
Manitex resumed with a Buy at Roth Capital
ARGX Argenx
$220.27 /

+5.82 (+2.71%)

06/16/20 SVB Leerink
Momenta's nipocalimab data positive for Immunovant '1401, says SVB Leerink
06/15/20 Stifel
Stifel reiterates Buy on Momenta following 'positive' nipocalimab results in MG
06/15/20 Piper Sandler
Piper Sandler reiterates Overweight on Momenta after 'solid' Nipocalimab data
05/29/20 JPMorgan
Argenx price target raised to $246 from $179 at JPMorgan
ALXN Alexion
$110.20 /

+0.97 (+0.89%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
IMVT Immunovant
$25.75 /

+1.8 (+7.52%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
ALXN Alexion
$110.20 /

+0.97 (+0.89%)

ALXN Alexion
$110.20 /

+0.97 (+0.89%)

ARGX Argenx
$220.27 /

+5.82 (+2.71%)

ALXN Alexion
$110.20 /

+0.97 (+0.89%)

ALXN Alexion
$110.20 /

+0.97 (+0.89%)

Recommendations
Piper says competitive updates present 'very little' potential impact on Alexion » 11:33
06/12/20
06/12
11:33
06/12/20
11:33
ALXN

Alexion

$108.43 /

-1.28 (-1.17%)

, APLS

Apellis

$31.37 /

+0.93 (+3.06%)

, VIE

Viela Bio

$46.73 /

-5.06 (-9.77%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond the full Phase 3 data from Apellis' (APLS) PEGASUS data confirms the rebound effect of adding a therapy then removing it, "but little else in our view." The data and color from the company's own key opinion leading physician leads him to believe pegcetacoplan, if approved, is likely to be indicated only in PNH for certain Soliris-inadequate responders, which Raymond notes is a shrinking market as Alexion (ALXN) continues to convert patients to Ultomiris. He also notes that Viela Bio's (VIE) inebilizumab was approved for NMOSD yesterday, but he remains "unconcerned" given the drug's "meaningful PML risk language," patient restrictions, and "inferior efficacy data" compared to Soliris. In all, Raymond views the two events as representing "another round of competitive concerns that add up to very little fundamental impact" on Alexion. He keeps an Overweight rating and $170 price target on Alexion shares.

ShowHide Related Items >><<
VIE Viela Bio
$46.73 /

-5.06 (-9.77%)

APLS Apellis
$31.37 /

+0.93 (+3.06%)

ALXN Alexion
$108.43 /

-1.28 (-1.17%)

ALXN Alexion
$108.43 /

-1.28 (-1.17%)

06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
APLS Apellis
$31.37 /

+0.93 (+3.06%)

04/28/20 Cantor Fitzgerald
Apellis price target raised to $61 from $54 at Cantor Fitzgerald
04/01/20 Raymond James
Apellis initiated with a Strong Buy at Raymond James
03/31/20 Raymond James
Apellis initiated with a Strong Buy at Raymond James
03/31/20 BMO Capital
Apellis initiated with an Outperform at BMO Capital
VIE Viela Bio
$46.73 /

-5.06 (-9.77%)

06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
06/08/20 Stifel
Viela Bio initiated with a Hold at Stifel
05/14/20 Guggenheim
Viela Bio price target raised to $78 from $51 at Guggenheim
VIE Viela Bio
$46.73 /

-5.06 (-9.77%)

APLS Apellis
$31.37 /

+0.93 (+3.06%)

ALXN Alexion
$108.43 /

-1.28 (-1.17%)

ALXN Alexion
$108.43 /

-1.28 (-1.17%)

VIE Viela Bio
$46.73 /

-5.06 (-9.77%)

APLS Apellis
$31.37 /

+0.93 (+3.06%)

ALXN Alexion
$108.43 /

-1.28 (-1.17%)

APLS Apellis
$31.37 /

+0.93 (+3.06%)

ALXN Alexion
$108.43 /

-1.28 (-1.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.